.
MergerLinks Header Logo

Announced

Boehringer Ingelheim to acquire NBE Therapeutics from PPF Group for c. €1.2bn.

Financials

Edit Data
Transaction Value£1,066m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pending

Private Equity

Switzerland

Single Bidder

Majority

Cross Border

biotechnology

Biotechnology

Private

Acquisition

Friendly

Synopsis

Edit

Boehringer Ingelheim, a research-driven pharmaceutical company, agreed to acquire NBE Therapeutics, a clinical-stage Swiss biotechnology company, from PPF Group, a private equity firm, for €1.18bn ($1.43bn). The closing of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021. “I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim. This transaction is a validation of our platform and its potential for the next generation cancer therapies. We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities,” Bertrand Damour, NBE Therapeutics. Chief Executive Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US